# AI News 180m Report｜2026-08-03 15:00–18:00 JST｜Page 6 of 6

One place for news and notices from 2 countries/regions: Japan, 353 items from 2 sources; Taiwan, 155 items from 4 sources.One edition every 180 minutes: every item from every source received in the period, with the original link.

## 長鑫科技 added to DRAM ETF! Ranks as its eighth-largest holding, with a 2.52% weighting

- Published: 2026-08-03T14:08:48+09:00
- Source: Taiwan | 鉅亨網
- Original: https://news.cnyes.com/news/id/6556113
- anchor: #n1799016
- Companies mentioned: 長鑫科技、兆易創新、三星電子、美光科技、SK海力士、希捷科技、威騰電子、SanDisk、鎧俠、南亞科、Roundhill Investments

Chinese DRAM maker 長鑫科技 was newly included in the world's first memory-focused ETF, DRAM ETF, with a 2.52% weighting, making it the eighth-largest holding. This marks an important step in the rising international recognition of Chinese semiconductor companies.

## 【豐達科】Press release—豐達’s July unaudited consolidated revenue totaled 4.94億元

- Published: 2026-08-02T01:00:00+09:00
- Source: Taiwan | 臺灣證券交易所
- Official text: https://mopsov.twse.com.tw/mops/web/ajax_t05st01?encodeURIComponent=1&step=2&firstin=1&off=1&queryName=co_id&inpuType=co_id&TYPEK=sii&co_id=3004&year=115&month=8&b_date=1&e_date=31&seq_no=1&spoke_time=141353&spoke_date=20260802
- anchor: #n1799570
- Companies mentioned: 豐達科技

豐達科 reported revenue of 494 million yuan in July 2026, down 0.65% month on month but up 53.03% year on year. Revenue for the first 7 months totaled 3.084 billion yuan, up 37.31% year on year, marking significant growth.

## 【華孚】Press release—華孚’s unaudited consolidated revenue for July 115年 totaled NT$550 million

- Published: 2026-08-02T01:00:00+09:00
- Source: Taiwan | 臺灣證券交易所
- Official text: https://mopsov.twse.com.tw/mops/web/ajax_t05st01?encodeURIComponent=1&step=2&firstin=1&off=1&queryName=co_id&inpuType=co_id&TYPEK=sii&co_id=6235&year=115&month=8&b_date=1&e_date=31&seq_no=1&spoke_time=140442&spoke_date=20260802
- anchor: #n1799569
- Companies mentioned: 華孚科技

華孚科技 reported self-consolidated revenue of 550 million yuan for July 115, up 2.32% month on month and 1.92% year on year. Revenue for the first 7 months totaled 3.767 billion yuan, up 2.30% year on year.

## [嘉威] The board meeting to review the financial report for the second quarter of 115 is scheduled for Aug. 10, 115.

- Published: 2026-08-02T01:00:00+09:00
- Source: Taiwan | 臺灣證券交易所
- Official text: https://mopsov.twse.com.tw/mops/web/ajax_t05st01?encodeURIComponent=1&step=2&firstin=1&off=1&queryName=co_id&inpuType=co_id&TYPEK=sii&co_id=3557&year=115&month=8&b_date=1&e_date=31&seq_no=1&spoke_time=131053&spoke_date=20260802
- anchor: #n1799568

嘉威 plans to hold a board meeting on Aug. 10, 115, to review its financial report for the second quarter. This is a routine financial disclosure and a material announcement; there are no other matters. Its significance lies in corporate transparency.

## 【科定】公告本公司115年第二季合併財務報告董事會預 計召開日期為115年08月10日

- Published: 2026-08-02T01:00:00+09:00
- Source: Taiwan | 臺灣證券交易所
- Official text: https://mopsov.twse.com.tw/mops/web/ajax_t05st01?encodeURIComponent=1&step=2&firstin=1&off=1&queryName=co_id&inpuType=co_id&TYPEK=sii&co_id=6655&year=115&month=8&b_date=1&e_date=31&seq_no=1&spoke_time=91107&spoke_date=20260802
- anchor: #n1799566

科定 announced that it will hold a board meeting on Aug. 10, 115, to review its consolidated financial report for the second quarter. This is a routine financial disclosure and important information for investors to track the company's financial developments.

## [藥華藥] Macau's Pharmaceutical Administration has approved an additional indication for BESREMi (Ropeginterferon alfa-2b) under its “imported medicine advance approval,” for essential thrombocythemia (ET).

- Published: 2026-07-31T01:00:00+09:00
- Source: Taiwan | 臺灣證券交易所
- Official text: https://mopsov.twse.com.tw/mops/web/ajax_t05st01?encodeURIComponent=1&step=2&firstin=1&off=1&queryName=co_id&inpuType=co_id&TYPEK=sii&co_id=6446&year=115&month=8&b_date=1&e_date=31&seq_no=1&spoke_time=125839&spoke_date=20260802
- anchor: #n1799567

BESREMi from 薬華薬 received a new indication in Macau for primary thrombocythemia. This is an important step in the company's global expansion and will contribute to market growth.

## Corrected Securities Report — 31st fiscal year (2025/04/01–2026/03/31)

- Published: 2026-08-03T15:47:00+09:00
- Source: Japan | EDINET 金融庁開示
- Original: https://api.edinet-fsa.go.jp/article/%E8%A8%82%E6%AD%A3%E6%9C%89%E4%BE%A1%E8%A8%BC%E5%88%B8%E5%A0%B1%E5%91%8A%E6%9B%B8%EF%BC%8D%E7%AC%AC31%E6%9C%9F(2025%2F04%2F01%EF%BC%8D2026%2F03%2F31)-2026-08-03%2015%3A47
- anchor: #n1799334
- Companies mentioned: LINEヤフー株式会社

LINEヤフー株式会社 has filed a corrected securities report for the 31st fiscal year.

## Corrected Securities Report — 187th fiscal year (2025/01/01–2025/12/31)

- Published: 2026-08-03T15:07:00+09:00
- Source: Japan | EDINET 金融庁開示
- Original: https://api.edinet-fsa.go.jp/article/%E8%A8%82%E6%AD%A3%E6%9C%89%E4%BE%A1%E8%A8%BC%E5%88%B8%E5%A0%B1%E5%91%8A%E6%9B%B8%EF%BC%8D%E7%AC%AC187%E6%9C%9F(2025%2F01%2F01%EF%BC%8D2025%2F12%2F31)-2026-08-03%2015%3A07
- anchor: #n1799148
- Companies mentioned: キリンホールディングス株式会社

キリンホールディングス株式会社 has filed a corrected securities report for the 187th fiscal year.